Novel Targets, Enhanced Donor Transplantation, Show Promise in Blood Cancers

Podcast

Stay tuned on this page for our upcoming coverage of the American Society of Clinical Oncology meeting 2010 focusing of hematologic malignancies.

Samuel Silver, MD, PhD

Samuel Silver, MD, PhD

Stay tuned on this page for our upcoming coverage of the American Society of Clinical Oncology meeting 2010 focusing of hematologic malignancies. To deliver the most insightful coverage, we have engaged nationally recognized hematology specialist, Samuel Silver, MD, PhD, Professor, Internal Medicine/Hematology-Oncology and Director of the University Cancer Center Network, University of Michigan Cancer Center, Ann Arbor, Michigan.

-Interviewed by Ron Piana

First up: An exclusive podcast interview-Dr. Silver elucidates the current trends and therapies for treating various blood cancers.

Next up: An expert perspective, gleaning the best hematologic highlights from this year’s meeting-Dr. Silver's clinical and research expertise spans bone marrow transplantation, malignant hematology, bleeding disorders, platelet dysfunction, myeloproliferative and myelodysplastic disorders and porphyria.

Watch this page for Dr. Silver's assessment of key sessions, abstracts, current therapies and future trends presented at the American Society of Clinical Oncology meeting 2010.

Recent Videos
Patients with AML will experience different toxicities based on the treatment they receive, whether it is intensive chemotherapy or targeted therapy.
A younger patient with AML who is more fit may be eligible for different treatments than an older patient with chronic medical conditions.
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Thomas Hope, MD, believes that an NRC initiative to update infiltration guidelines may organically address concerns that H.R. 2541 outlines.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
4 experts are featured in this series.
4 experts are featured in this series.
Related Content
Rising cancer diagnoses in the US highlight urgent needs for improved oncology education, workforce distribution, and care infrastructure, especially in rural areas.

A Decline in the US Oncology Workforce: What Will the Next Decade Bring?

Julie M. Vose, MD, MBA
December 2nd 2025
Article

Rising cancer diagnoses in the US highlight urgent needs for improved oncology education, workforce distribution, and care infrastructure, especially in rural areas.

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Evolutions Across NSCLC, Multiple Myeloma, and AML at Georgia Cancer Center

Girindra Raval, MD;Amany Keruakous, MD;Daniel Peters, MD
December 1st 2025
Podcast

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

ONCOLOGY Editorial Advisory Board Member Dies from Glioblastoma

ONCOLOGY Editorial Advisory Board Member Dies from Glioblastoma

Ariana Pelosci
December 1st 2025
Article

Edward Chu, MD, a member of the gastrointestinal editorial advisory board, died of glioblastoma in November.

Decision-Making Capacity: The Ethical Core of Patient-Centered Oncology

Decision-Making Capacity: The Ethical Core of Patient-Centered Oncology

Daniel C. McFarland, DO;Louis P. Voigt, MD;Yesne Alici, MD
November 24th 2025
Podcast

Daniel C. McFarland, DO, is joined by Louis P. Voigt, MD, and Yesne Alici, MD, who focused on decision-making capacity and patient-centered care.

The developers plan to submit a new drug application to regulatory authorities for JS001sc for the treatment of first-line non-squamous NSCLC.

Subcutaneous Toripalimab Meets Primary End Points in Nonsquamous NSCLC

Roman Fabbricatore
November 30th 2025
Article

The developers plan to submit a new drug application to regulatory authorities for JS001sc for the treatment of first-line nonsquamous NSCLC.

According to Daniel Peters, MD, the recent FDA approvals of revumenib and ziftomenib in AML are some of the most exciting developments in the field.

The Paradigm of AML Care: What’s New and What’s Changing

Tim Cortese
November 30th 2025
Article

According to Daniel Peters, MD, the recent FDA approvals of revumenib and ziftomenib in AML are some of the most exciting developments in the field.